In summary, this pilot study has suggested that the administration of 10 mg of zibotentan has a positive impact on reducing angina frequency in patients with refractory angina attributed to the CSFP, underscoring the potential therapeutic efficacy of targeting the ET-1 pathway in this specific disorder. Here, EDN1 is linked to angina pectoris.